Video

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

Author(s):

Sandy Wong, MD

In Partnership With:

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

One candidate is the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121), which demonstrated an overall response rate (ORR) of 73.4% and a median progression-free survival of 8.6 months in patients with relapsed/refractory disease in the phase II KarMMA trial.

JNJ-4528, another BCMA-targeted product, achieved a 100% ORR in the phase Ib/II CARTITUDE-1 trial in patients with heavily pretreated relapsed/refractory multiple myeloma. These results supplement data from the Chinese LEGEND-2 study (NCT03090659) which is investigating the same product in a slightly different patient population.

These data indicate that moving CAR T-cell therapy to an earlier line of treatment may enhance response for patients, concludes Wong.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
Syed Abbas Ali, MBBS
November 22nd 2024

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

The University of California San Francisco
November 11th 2024

UC Regents Approve UCSF Proton Therapy Center for Cancer Care

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

FDA
November 8th 2024

FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology